Zomedica Announces Achievement of Therapeutic Development Milestones
12 déc. 2017 06h55 HE
|
Zomedica Pharmaceuticals Corp.
ANN ARBOR, Mich., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary pharmaceutical and diagnostic company,...
Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose Intolerance
03 oct. 2017 12h00 HE
|
Ritter Pharmaceuticals
Los Angeles, California,, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...
FDA Commissioner Scott Gottlieb to Deliver Keynote at RAPS Regulatory Convergence
03 juil. 2017 09h00 HE
|
Regulatory Affairs Professionals Society (RAPS)
Rockville, MD, USA, July 03, 2017 (GLOBE NEWSWIRE) -- US Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, will address the global regulatory community on 10 September, delivering...
Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
19 juin 2017 16h30 HE
|
Melinta Therapeutics
- Baxdela offers a new option for treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) including hospital-treated skin infections in oral and IV formulations as...
Melinta Therapeutics Announces FDA Acceptance of Investigational New Drug Application for Topical Radezolid
28 févr. 2017 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today the U.S. Food...
CapsoVision, Inc. Announces FDA 510(k) Clearance for CapsoCam® Plus
11 nov. 2016 15h43 HE
|
CapsoVision Inc.
SARATOGA, Calif., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Silicon Valley medical device innovator CapsoVision, Inc. is pleased to announce that they have received U.S. Food and Drug Administration (FDA)...
Medstar Union Memorial Hospital Makes Pioneering Strides in Coronary Care
08 août 2016 17h53 HE
|
MedStar Health
BALTIMORE, MD--(Marketwired - August 08, 2016) - MedStar Union Memorial Hospital became the first and only hospital in Maryland to offer a fully dissolvable cardiac stent to patients fighting coronary...
American College of Rheumatology Encourages Safe Adoption of Biosimilars During FDA Public Hearing on CT-P13, a Proposed Biosimilar for Infliximab (Remicade)
10 févr. 2016 14h43 HE
|
American College of Rheumatology
ATLANTA, Feb. 10, 2016 (GLOBE NEWSWIRE) -- During a public meeting held Tuesday by the Food and Drug Administration (FDA)'s Arthritis Advisory Committee to review the license application of CT-P13,...
![ENT and Allergy logo](/news-release/logo/381190/0/381190.jpg?lastModified=12%2F09%2F2016%2023%3A09%3A19&size=2)
ENT and Allergy Associates(R) Announce ImThera Medical Clinical Study
28 mai 2015 14h48 HE
|
Ent and Allergy
TARRYTOWN, N.Y., May 28, 2015 (GLOBE NEWSWIRE) -- The following is a message from Dr. Ofer Jacobowitz, partner of ENT and Allergy Associates:
Sleep apnea is a serious and dangerous disease where...
Relmada Therapeutics Set for Busy 2015 in Clinical Trials Developing Drugs for the Lucrative Pain Market
02 avr. 2015 08h30 HE
|
Relmada Therapeutics, Inc.
NEW YORK, NY--(Marketwired - April 02, 2015) - Relmada Therapeutics, Inc. (OTCQB: RLMD) has quite a busy 2015 ahead of it in the clinic. The pharmaceutical company has stepped up its work in a big...